SBIR/STTR Research Award

AMINE OXIDASE-DEPLETED CELL CULTURE MEDIA FOR STEM CELLS

Award identifier f8051ed985d0a749ad371d219eb19be4655a5690b1634daab17975ab9c1dc473Awarding agency Department of Health and Human Services

Award amount

$512,000

Program and phase

SBIR · Phase II

Award year

1994

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Hipple Cancer Research
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

A FAMILY OF PLASMA ENZYMES NAMED AMINE OXIDASES CONTRIBUTE TO A LACK OF SURVIVAL OF HEMATOPOIETIC PROGENITOR CELLS IN VITRO BY OXIDIZING THE AMINES RELEASED INTO THE MEDIUM INTO CYTOTOXIC AND MUTAGENIC HYDROGEN PEROXIDE AND ALDEHYDES. THIS SHORT-TERM TOXICITY MANIFESTS AS LOW CLONING EFFICIENCIES. INHIBITORS OF PLASMA AMINE OXIDASES PREVENT THESE TOXIC EFFECTS AND INCREASE CLONING EFFICIENCIES FOR MURINE CFU-ERYTHROID AND CFU-GRANULOCYTE/MACROPHAGE. THESE INHIBITORS CAN SUBSTITUTE FOR 2-MERCAPTOETHANOL IN THE CFU-E ASSAY, PROVIDING AN EXPLANATION FOR THE STIMULATORY EFFECTS OF THIOLS ORIGINALLY DISCOVERED BY ISCOVE. HOWEVER, THESE ENZYME INHIBITORS ARE TOXIC TO HUMAN CELLS, SO OTHER APPROACHES ARE NEEDED TO ELIMINATE AMINE OXIDASE TOXICITY. SERUM-FREE MEDIA DO NOT NECESSARILY CIRCUMVENT THIS PROBLEM, BECAUSE MANY "PURIFIED" PROTEINS OR ADDITIVES REQUIRED FOR THESE MEDIA CONTAIN AMINE OXIDASES AS CONTAMINANTS. THESE ENZYMES ALSO CAUSE LONG-TERM TOXICITY, SUCH AS THE CRISIS OF SPONTANEOUS TRANSFORMATION IN CULTURES OF MOUSE EMBRYO CELLS. THESE DATA SUGGEST THAT AMINE OXIDASE TOXICITY IS UBIQUITOUS IN VITRO, AND, FURTHERMORE, THAT THE DEVELOPMENT OF CULTURE SUPPLEMENTS DEVOID OF AMINE OXIDASES MAY FACILITATE ADVANCES IN THE STUDY AND MANIPULATION OF STEM CELLS EX VIVO. IN PHASE I, WE WILL DETERMINE WHICH PLASMA AMINE OXIDASES CAUSE TOXICITY. IN PHASE II, WE WILL DEVELOP TECHNOLOGY TO ELIMINATE DELETERIOUS AMINE OXIDASES FROM THE CULTURE SUPPLEMENTS, CONFIRM THAT THEIR ELIMINATION PREVENTS SHORT- AND LONG-TERM TOXICITIES, AND APPLY THIS NEW CELL CULTURE TECHNOLOGY TOWARD THE DEVELOPMENT OF STEM CELL LINES FROM NORMAL AND MALIGNANT HUMAN BONE MARROW, BREAST, PROSTATE, AND LYMPH NODE, INCLUDING LYMPHOMAS. SUCH CELL LINES MAY PROVE VALUABLE FOR CARCINOGENESIS AND MUTAGENESIS STUDIES, FOR IN VITRO ASSAYS FOR IDENTIFYING NEW ANTI-CANCER DRUGS, AND FOR STABILIZING THE GENOME OF HYBRIDOMAS (CURRENTLY CULTURED IN 2-MERCAPTOETHANOL). THE TECHNOLOGY HOLDS PROMISE FOR A BASE FROM WHICH MANY OF THE IN VITRO GOALS OF "HEALTHY PEOPLE-2000" MAY BE ACHIEVED.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.